SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Sick Visit — Lili Boulanger

PatientLili Boulanger
Date of birth2004-08-21
IdentifiersMRN HR-ET025-SYN; SSN (made up) 000-25-7731
Document date2026-04-13
AuthorOdile Marchetti-Rowe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Vomiting and watery diarrhea since yesterday. [S]

History of Present Illness

Ms. Boulanger is a 21-year-old woman with ileocolonic Crohn disease, ten weeks into risankizumab and in clinical remission since the prednisone taper ended three weeks ago. Yesterday evening she developed sudden nausea and vomiting, six times overnight, then watery, non-bloody diarrhea eight times since, with cramping across the whole abdomen, aching, and a temperature of 37.8 °C at home. Two of her fellow musicians in the same rehearsal group were ill with the same symptoms this week. She has had no antibiotics. She is keeping down small sips. She wanted to know whether this was her Crohn disease returning and whether she should delay her next risankizumab dose. [S]

ElementDetail
OnsetSudden, yesterday evening
LocationWhole abdomen, cramping
DurationAbout 18 hours
CharacterVomiting, then watery non-bloody diarrhea
SeverityModerate; mild dehydration
ContextContacts ill with the same symptoms; no antibiotics; on risankizumab
Modifying factorsSmall sips tolerated since this morning
Associated signs and symptomsLow-grade fever, aching; no blood, no right lower quadrant pain like her Crohn pain

Review of Systems

SystemResultFinding
ConstitutionalPositiveLow-grade fever and aching
GastrointestinalPositiveVomiting and watery diarrhea; no blood; cramps across the whole abdomen
GenitourinaryPositivePassing less urine than usual
CardiovascularPositiveLight-headed on standing
IntegumentaryNegativeNo rash or yellowing

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugsOne or two tablets up to every 6 hours as neededOral route2025-12-15activeS
Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect40 mg each morning, tapering by 5 mg weeklyOral route2026-01-28 to 2026-03-24completedS
Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction)One infusion every 4 weeks for three dosesIntravenous route2026-02-02 to 2026-04-26completedS
Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single doseSingle infusionIntravenous route2026-02-02 to 2026-02-02completedS
Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-01-28activeS
Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisoneOne tablet daily with foodOral route2026-01-28 to 2026-03-24completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-13Body height160cmS
2026-04-13Body weight46.9kgS
2026-04-13Body mass index (BMI) [Ratio]18.3kg/m2S
2026-04-13Systolic blood pressure98mm[Hg]S
2026-04-13Diastolic blood pressure62mm[Hg]S
2026-04-13Heart rate98/minS
2026-04-13Respiratory rate16/minS
2026-04-13Body temperature37.7CelS
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-13Leukocytes [#/volume] in Blood by Automated count9.410*3/uL4-11 10*3/uLNormalS
2026-04-13C reactive protein [Mass/volume] in Serum or Plasma11mg/L<=5 mg/LHighS
2026-04-13Potassium [Moles/volume] in Serum or Plasma3.4mmol/L3.5-5.1 mmol/LLowS
2026-04-13Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.5-1.1 mg/dLNormalS
2026-04-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L<=33 U/LNormalS

Physical Exam

Vital signs recorded on 2026-04-13; see the Vital Signs section. [S]

SystemFinding
GeneralTired, mildly dehydrated; temperature 37.7 °C; heart rate 98
MouthDry mucous membranes; no ulcers
AbdomenSoft, mildly tender everywhere without guarding; active bowel sounds; no right lower quadrant mass
PerianalNormal

Problems

ProblemClinical statusVerificationCodeProvenance
Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settledactiveconfirmed K50.80S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed.
Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging bookedresolvedconfirmed R19.7S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D).
Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9)activeconfirmed D50.0S — Synthetic finding at presentation; corrected by intravenous iron.
Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dLactiveconfirmed E44.0S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support.
Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL)activeconfirmed E55.9S — Synthetic finding at presentation.
Long-term use of risankizumab, an immunosuppressive biologic, for Crohn diseaseactiveconfirmed Z79.620S — Synthetic treatment status.
Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three daysresolvedconfirmed A08.11S — Synthetic common infection that teaches the difference between infection and a flare in treated Crohn disease; it does not echo a documented illness.

Assessment and Plan

Guideline basis: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2026 (2026); 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis 2017;65(12):e45-e80 (2017)

Follow-up: Telephone check in two days. IBD review as planned at the first maintenance dose. Next scheduled visit 2026-04-27: review at week 12, the first maintenance dose of risankizumab. [S]